Humacyte, Inc. (NASDAQ:HUMA) Short Interest Up 34.9% in December

Humacyte, Inc. (NASDAQ:HUMA) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 29,620,000 shares, an increase of 34.9% from the December 15th total of 21,960,000 shares. Based on an average daily trading volume, of 4,700,000 shares, the short-interest ratio is currently 6.3 days. Approximately 28.4% of the shares of the company are sold short.

Humacyte Price Performance

Shares of NASDAQ HUMA opened at $4.41 on Friday. The firm’s 50-day moving average is $4.58 and its two-hundred day moving average is $5.66. The company has a market capitalization of $555.04 million, a PE ratio of -3.29 and a beta of 1.32. Humacyte has a 12-month low of $2.53 and a 12-month high of $9.97.

Insider Activity at Humacyte

In other news, Director Brady W. Dougan sold 427,459 shares of the firm’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the sale, the director now owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. This trade represents a 17.67 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Laura E. Niklason sold 261,369 shares of the business’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total transaction of $1,150,023.60. Following the transaction, the chief executive officer now owns 1,730,884 shares in the company, valued at approximately $7,615,889.60. This trade represents a 13.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,500,000 shares of company stock worth $6,606,799 in the last three months. Insiders own 11.20% of the company’s stock.

Institutional Investors Weigh In On Humacyte

Institutional investors and hedge funds have recently bought and sold shares of the stock. Brookstone Capital Management acquired a new position in shares of Humacyte in the fourth quarter worth $56,000. ACT Wealth Management LLC acquired a new position in Humacyte in the 4th quarter valued at about $57,000. Concurrent Investment Advisors LLC purchased a new position in Humacyte in the 3rd quarter valued at about $75,000. FORA Capital LLC acquired a new stake in shares of Humacyte during the 3rd quarter worth about $96,000. Finally, Profund Advisors LLC purchased a new stake in shares of Humacyte during the second quarter worth about $97,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on HUMA shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.00 price objective on shares of Humacyte in a report on Friday, September 20th. TD Cowen reiterated a “buy” rating and issued a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the company a “neutral” rating in a research note on Friday, October 18th. D. Boral Capital restated a “buy” rating and set a $25.00 target price on shares of Humacyte in a research report on Monday, January 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 price target (up from $12.00) on shares of Humacyte in a research report on Friday, December 20th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Humacyte has a consensus rating of “Buy” and an average target price of $13.71.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.